Lv31
400 积分 2024-07-23 加入
10.1182/b OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML
1个月前
已完结
Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma
2个月前
已完结
Real-world efficacy of Bruton tyrosine kinase inhibitor based maintenance therapy in diffuse large B-cell lymphoma: a multicenter retrospective cohort study with external historical control
3个月前
已完结
Real-world efficacy of Bruton tyrosinekinase inhibitorbased maintenance therapyindiffuselargeB-cell lymphoma:amulticenterretrospective cohortstudywithexternalhistoricalcontrol
3个月前
已关闭
A Metabolically Optimized, Noncytotoxic Low - Dose Weekly Decitabine/Venetoclax in MDS and AML
3个月前
已完结
Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma
5个月前
已关闭
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
6个月前
已完结
皖公网安备34019202002308
